- Home
- DAWN vs ESE Comparison
DAWN vs ESE Comparison
Compare DAWN & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- ESE
- Stock Information
- Founded
- DAWN 2018
- ESE 1990
- Country
- DAWN United States
- ESE United States
- Employees
- DAWN N/A
- ESE N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- ESE Telecommunications Equipment
- Sector
- DAWN Health Care
- ESE Telecommunications
- Exchange
- DAWN Nasdaq
- ESE Nasdaq
- Market Cap
- DAWN 1.3B
- ESE N/A
- IPO Year
- DAWN 2021
- ESE N/A
- Fundamental
- Price
- DAWN $12.79
- ESE $135.31
- Analyst Decision
- DAWN Strong Buy
- ESE Buy
- Analyst Count
- DAWN 7
- ESE 3
- Target Price
- DAWN $36.17
- ESE $137.67
- AVG Volume (30 Days)
- DAWN 937.9K
- ESE 93.3K
- Earning Date
- DAWN 10-30-2024
- ESE 02-06-2025
- Dividend Yield
- DAWN N/A
- ESE 0.24%
- EPS Growth
- DAWN N/A
- ESE 10.06
- EPS
- DAWN N/A
- ESE 3.94
- Revenue
- DAWN $101,953,000.00
- ESE $1,026,759,000.00
- Revenue This Year
- DAWN N/A
- ESE $14.05
- Revenue Next Year
- DAWN $36.10
- ESE $11.19
- P/E Ratio
- DAWN N/A
- ESE $34.25
- Revenue Growth
- DAWN N/A
- ESE 7.40
- 52 Week Low
- DAWN $11.94
- ESE $96.69
- 52 Week High
- DAWN $18.07
- ESE $154.00
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- ESE 39.20
- Support Level
- DAWN $12.26
- ESE $131.31
- Resistance Level
- DAWN $12.81
- ESE $146.15
- Average True Range (ATR)
- DAWN 0.52
- ESE 3.10
- MACD
- DAWN -0.05
- ESE -1.81
- Stochastic Oscillator
- DAWN 28.94
- ESE 22.22
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.